However, as the EC regimen did not address the ALK-positive adenocarcinoma component, there was a risk that the ALK-positive adenocarcinoma could grow and metastasize as a non-dominant subclone, warranting an ALK-targeted approach to prevent progression. Here, ALK is linked to adenocarcinoma.